EUVIMEDEUVIMED entdecken
Open Access

Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer

Loretah Chibaya iD, Kelly D DeMarco iD, Christina F Lusi iD, Griffin I Kane iD, Meghan L Brassil iD, Chaitanya N Parikh, Katherine C Murphy iD, Shreya R Chowdhury iD, Junhui Li iD, Boyang Ma iD, Tiana E Naylor iD, Julia Cerrutti iD und 8 weitere

Science Translational Medicine · 28.08.2024 · 16 (762)

DOI: 10.1126/scitranslmed.adj9366 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 28.08.2024. Verfasst von Loretah Chibaya und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA. Hauptthemen laut MEDLINE: Immunity, Innate, Pancreatic Neoplasms, Nanoparticles, Tumor Microenvironment. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) has quickly risen to become the third leading cause of cancer-related death in the United States. This is in part because of its fibrotic tumor microenvironment (TME) that contributes to poor vascularization and immune infiltration and subsequent chemo- and immunotherapy failure. Here, we investigated an immunotherapy approach combining delivery of stimulator of interferon genes (STING) and Toll-like receptor 4 (TLR4) innate immune agonists by lipid-based nanoparticle (NP) coencapsulation with senescence-inducing RAS-targeted therapies, which can remodel the immune suppressive PDAC TME through the senescence-associated secretory phenotype. Treatment of transplanted and autochthonous PDAC mouse models with these regimens led to enhanced uptake of NPs by multiple cell types in the PDAC TME, induction of type I interferon and other proinflammatory signaling pathways, increased antigen presentation by tumor cells and antigen-presenting cells, and subsequent activation of both innate and adaptive immune responses. This two-pronged approach produced potent T cell–driven and type I interferon–mediated tumor regression and long-term survival in preclinical PDAC models dependent on both tumor and host STING activation. STING and TLR4-mediated type I interferon signaling was also associated with enhanced natural killer and CD8 + T cell immunity in human PDAC samples. Thus, combining localized immune agonist delivery with systemic tumor-targeted therapy can orchestrate a coordinated type I interferon–driven innate and adaptive immune response with durable antitumor efficacy against PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunity, InnatePancreatic NeoplasmsNanoparticlesTumor MicroenvironmentCarcinoma, Pancreatic DuctalToll-Like Receptor 4AnimalsHumansMiceT-LymphocytesInterferon Type ICell Line, TumorImmunotherapyCellular SenescenceMembrane ProteinsMice, Inbred C57BLSignal Transduction

Substanzen

Toll-Like Receptor 4Interferon Type IMembrane Proteins

Autor:innen und Institutionen

  • Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
  • Department of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA 01003, USA.
  • Division of Innate Immunity, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
  • Division of Hematology-Oncology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
  • Program in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
  • Department of Genomics and Computational Biology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.

ORCID-Profile: Loretah Chibaya, Kelly D DeMarco, Christina F Lusi, Griffin I Kane, Meghan L Brassil, Katherine C Murphy, Shreya R Chowdhury, Junhui Li, Boyang Ma, Tiana E Naylor, Julia Cerrutti, Miranda Diaz-Infante, Jessica Peura, Jason R Pitarresi, Lihua Julie Zhu, Katherine A Fitzgerald, Prabhani U Atukorale, Marcus Ruscetti

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Chibaya, L., DeMarco, K. D., Lusi, C. F., Kane, G. I., Brassil, M. L., Parikh, C. N., Murphy, K. C., Chowdhury, S. R., Li, J., Ma, B., Naylor, T. E., Cerrutti, J., Mori, H., Diaz-Infante, M., Peura, J., Pitarresi, J. R., Zhu, L. J., Fitzgerald, K. A., Atukorale, P. U., & Ruscetti, M. (2024). Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer. Science Translational Medicine, 16(762). https://doi.org/10.1126/scitranslmed.adj9366

Vancouver

Chibaya L, DeMarco KD, Lusi CF, Kane GI, Brassil ML, Parikh CN, et al. Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer. Science Translational Medicine. 2024;16(762). doi:10.1126/scitranslmed.adj9366

BibTeX
@article{Chibaya2024,
  author = {Chibaya, Loretah and DeMarco, Kelly D and Lusi, Christina F and Kane, Griffin I and Brassil, Meghan L and Parikh, Chaitanya N and Murphy, Katherine C and Chowdhury, Shreya R and Li, Junhui and Ma, Boyang and Naylor, Tiana E and Cerrutti, Julia and Mori, Haruka and Diaz-Infante, Miranda and Peura, Jessica and Pitarresi, Jason R and Zhu, Lihua Julie and Fitzgerald, Katherine A and Atukorale, Prabhani U and Ruscetti, Marcus},
  title = {Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer},
  journal = {Science Translational Medicine},
  year = {2024},
  volume = {16},
  number = {762},
  doi = {10.1126/scitranslmed.adj9366}
}
Kostenlos starten →